Edition:
United Kingdom

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,429
52-wk High
$1.24
52-wk Low
$0.34

Chart for

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $27.16
Shares Outstanding(Mil.): 35.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

07 Dec 2017

BRIEF-Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​

* Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​

13 Nov 2017

BRIEF-Heat Biologics Inc files for mixed shelf of up to $50 million ‍​

* Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​ Source text - (http://bit.ly/2ltFdsE) Further company coverage:

30 Oct 2017

BRIEF-Heat Biologics sets subscription price of $0.62/shr for its intended rights offering to certain existing security holders

* Says subscription price of $0.62 per share for its intended rights offering to certain of co's existing security holders - SEC filing​ Source text for Eikon: (http://bit.ly/2wZmeaM) Further company coverage:

16 Oct 2017

BRIEF-Heat Biologics been granted type C meeting with FDA

* Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo Source text: (http://bit.ly/2wY2UeW) Further company coverage:

12 Sep 2017

Earnings vs. Estimates